Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During ERCP (Anricofen Cipr)

5 de noviembre de 2026 actualizado por: The First Affiliated Hospital of Xinxiang Medical College

Comparison of Postoperative Recovery Quality and Safety Between Anricofen Combined With Ciprofol and Sufentanil Combined With Ciprofol for Non-intubated Anesthesia During Endoscopic Retrograde Cholangiopancreatography: A Randomized Controlled Trial

This study aims to compare postoperative recovery quality and safety between anricofen combined with ciprofol and sufentanil combined with ciprofol in patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) under non-intubated anesthesia.

This is a single-center, prospective, randomized, controlled study involving patients aged 18-80 years who are scheduled for elective ERCP. A total of 180 participants are planned to be enrolled and randomly assigned in a 1:1 ratio to two groups.

Participants in the anricofen group will receive intravenous anricofen (HSK21542) at a dose of 1 μg/kg before ciprofol induction. Participants in the sufentanil group will receive intravenous sufentanil at a dose of 0.1 μg/kg before ciprofol induction. Both groups will receive ciprofol for anesthesia induction and maintenance.

The primary outcome is the total Quality of Recovery-15 (QoR-15) score at 24 hours after the procedure. Secondary outcomes include postoperative pain scores at different time points, total ciprofol consumption, recovery time, post-anesthesia care unit stay, respiratory and hemodynamic adverse events, postoperative nausea and vomiting, and serious adverse events.

The study is expected to provide clinical evidence on the postoperative recovery quality and safety of these two analgesic regimens for patients undergoing ERCP under non-intubated anesthesia.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

180

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Longhua Guo
  • Número de teléfono: 18303733012
  • Correo electrónico: 1535732839@qq.com

Ubicaciones de estudio

    • Henan
      • Xinxiang, Henan, Porcelana
        • Reclutamiento
        • The First Affiliated Hospital of Henan Medical University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 80 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

**Inclusion Criteria:**

  1. Aged 18 to 80 years;
  2. American Society of Anesthesiologists (ASA) physical status I to III;
  3. Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP).

**Exclusion Criteria:**

  1. Pregnancy or lactation;
  2. Obstructive sleep apnea (OSA);
  3. Long-term use of analgesics or psychotropic drugs, or a history of drug abuse;
  4. Coagulation dysfunction, bleeding tendency, or current anticoagulant therapy;
  5. Allergy to any of the study drugs;
  6. Severe cardiac, hepatic, renal, or other major organ diseases;
  7. Mental or cognitive impairment that prevents cooperation with the assessment;
  8. Inability to comply with the study protocol or complete follow-up;
  9. Requirement for tracheal intubation, postoperative transfer to the intensive care unit (ICU), or postoperative pancreatitis.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Anricofen(HSK21542) 1 μg/kg + Ciprofol

Anricofen (HSK21542) is a peripherally restricted κ-opioid receptor agonist. In this study, it is administered intravenously at a dose of 1 μg/kg 3 minutes before ciprofol induction by slow injection.

Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses.

Comparador activo: Sufentanil 0.1 μg/kg + Ciprofol

Ciprofol is an intravenous sedative agent used for anesthesia induction and maintenance in this study. It is administered intravenously at an induction dose of 0.3 mg/kg by slow injection over more than 30 seconds. After the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score reaches 3 or below, ERCP is initiated. Anesthesia is maintained with a continuous infusion of ciprofol at 1.0-2.0 mg/kg/h. If patient movement or eye opening occurs during the procedure, an additional bolus of 0.10-0.15 mg/kg may be administered, with an interval of at least 2 minutes between additional doses.

Sufentanil is an opioid analgesic. In this study, it is used as the active comparator and administered intravenously at a dose of 0.1 μg/kg 3 minutes before ciprofol induction by slow injection.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Quality of Recovery-15 (QoR-15) Score at 24 Hours Postoperatively
Periodo de tiempo: 24 hours after the procedure

The primary outcome is the total score of the Quality of Recovery-15 (QoR-15) questionnaire at 24 hours after ERCP. The QoR-15 is a patient-reported measure of postoperative recovery quality, with total scores ranging from 0 to 150. Higher scores indicate better postoperative recovery quality.

24 hours after the procedure

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Resting Numerical Rating Scale (NRS) Pain Score
Periodo de tiempo: At prespecified time points postoperatively

Resting pain intensity will be assessed using the Numerical Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain), at the prespecified postoperative assessment time points.

At prespecified time points postoperatively
Total Ciprofol Consumption
Periodo de tiempo: During the ERCP procedure

The total dose of ciprofol administered to each participant during the ERCP procedure will be recorded and compared between the two groups.

During the ERCP procedure
Respiratory and Hemodynamic Adverse Events
Periodo de tiempo: During the procedure and up to 24 hours postoperatively

The incidence and details of perioperative respiratory and hemodynamic adverse events will be recorded. Respiratory events include hypoxemia, apnea or significant hypoventilation, airway interventions, mask-assisted ventilation, supraglottic airway placement, and emergency tracheal intubation. Hemodynamic events include hypotension, bradycardia, and the use of vasoactive drugs such as norepinephrine or atropine.

During the procedure and up to 24 hours postoperatively
Postoperative Nausea and Vomiting (PONV)
Periodo de tiempo: Within 24 hours postoperatively

The occurrence of postoperative nausea and vomiting will be recorded and compared between the two groups.

Within 24 hours postoperatively
Serious Adverse Events (SAEs)
Periodo de tiempo: From enrollment until the end of the study

The occurrence, type, and details of serious adverse events will be recorded throughout the study period.

From enrollment until the end of the study
Recovery Time
Periodo de tiempo: From the end of the ERCP procedure to recovery

The time required for participants to recover from anesthesia after the ERCP procedure will be recorded and compared between the two groups.

From the end of the ERCP procedure to recovery
Post-Anesthesia Care Unit (PACU) Length of Stay
Periodo de tiempo: From PACU admission to PACU discharge

The duration of stay in the post-anesthesia care unit (PACU) after the procedure will be recorded and compared between the two groups.

From PACU admission to PACU discharge

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de enero de 2026

Finalización primaria (Estimado)

1 de marzo de 2028

Finalización del estudio (Estimado)

1 de mayo de 2028

Fechas de registro del estudio

Enviado por primera vez

16 de enero de 2026

Primero enviado que cumplió con los criterios de control de calidad

26 de enero de 2026

Publicado por primera vez (Actual)

29 de enero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

9 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • XYFY-IIT-ANES-ERCP-2025-01

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir